Net revenues from Events Production Increased by 376.5% YoY
Total operating expenses reduced by 49% YoY, narrowing net loss by 59%
Leveraging core competencies to create an expansive digital entertainment ecosystem with diverse revenue streams.
- TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma - December 8, 2024
- Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - December 8, 2024
- Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma - December 8, 2024